Annual CFO
-$1.79 M
-$6.20 M-140.55%
31 December 2023
Summary:
Anika Therapeutics annual cash flow from operations is currently -$1.79 million, with the most recent change of -$6.20 million (-140.55%) on 31 December 2023. During the last 3 years, it has fallen by -$14.85 million (-113.69%). ANIK annual CFO is now -104.38% below its all-time high of $40.81 million, reached on 31 December 2017.ANIK Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$5.02 M
+$6.08 M+569.22%
30 September 2024
Summary:
Anika Therapeutics quarterly cash flow from operations is currently $5.02 million, with the most recent change of +$6.08 million (+569.22%) on 30 September 2024. Over the past year, it has dropped by -$1.47 million (-22.65%). ANIK quarterly CFO is now -74.37% below its all-time high of $19.57 million, reached on 31 March 2004.ANIK Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$7.46 M
-$1.47 M-16.45%
30 September 2024
Summary:
Anika Therapeutics TTM cash flow from operations is currently $7.46 million, with the most recent change of -$1.47 million (-16.45%) on 30 September 2024. Over the past year, it has increased by +$12.40 million (+250.84%). ANIK TTM CFO is now -83.04% below its all-time high of $43.97 million, reached on 31 March 2016.ANIK TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANIK Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -140.6% | -22.6% | +250.8% |
| 3 y3 years | -113.7% | +143.3% | +14.5% |
| 5 y5 years | -105.1% | -50.1% | -78.1% |
ANIK Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -113.7% | at low | -22.6% | +160.5% | -16.7% | +185.5% |
| 5 y | 5 years | -104.8% | at low | -61.5% | +160.5% | -79.8% | +185.5% |
| alltime | all time | -104.4% | +58.6% | -74.4% | +160.5% | -83.0% | +185.5% |
Anika Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $5.02 M(-569.2%) | $7.46 M(-16.5%) |
| June 2024 | - | -$1.07 M(+748.4%) | $8.93 M(+423.9%) |
| Mar 2024 | - | -$126.00 K(-103.5%) | $1.70 M(-195.3%) |
| Dec 2023 | -$1.79 M(-140.6%) | $3.64 M(-43.9%) | -$1.79 M(-63.8%) |
| Sept 2023 | - | $6.49 M(-178.2%) | -$4.95 M(-43.3%) |
| June 2023 | - | -$8.29 M(+129.2%) | -$8.72 M(-427.9%) |
| Mar 2023 | - | -$3.62 M(-852.2%) | $2.66 M(-39.7%) |
| Dec 2022 | $4.41 M(-47.5%) | $481.00 K(-82.2%) | $4.41 M(-47.5%) |
| Sept 2022 | - | $2.71 M(-12.3%) | $8.40 M(+8.3%) |
| June 2022 | - | $3.09 M(-265.2%) | $7.75 M(-13.5%) |
| Mar 2022 | - | -$1.87 M(-141.8%) | $8.96 M(+6.7%) |
| Dec 2021 | $8.40 M(-35.7%) | $4.47 M(+116.9%) | $8.40 M(+28.9%) |
| Sept 2021 | - | $2.06 M(-52.0%) | $6.51 M(-36.9%) |
| June 2021 | - | $4.29 M(-276.6%) | $10.31 M(+7.6%) |
| Mar 2021 | - | -$2.43 M(-194.0%) | $9.59 M(-26.6%) |
| Dec 2020 | $13.06 M(-64.7%) | $2.59 M(-55.9%) | $13.06 M(-44.4%) |
| Sept 2020 | - | $5.87 M(+64.4%) | $23.50 M(-15.1%) |
| June 2020 | - | $3.57 M(+241.4%) | $27.69 M(-6.4%) |
| Mar 2020 | - | $1.04 M(-92.0%) | $29.59 M(-20.0%) |
| Dec 2019 | $37.01 M(+6.0%) | $13.02 M(+29.6%) | $37.01 M(+8.9%) |
| Sept 2019 | - | $10.05 M(+83.7%) | $34.00 M(-2.3%) |
| June 2019 | - | $5.47 M(-35.4%) | $34.79 M(+3.0%) |
| Mar 2019 | - | $8.46 M(-15.5%) | $33.79 M(-3.2%) |
| Dec 2018 | $34.92 M(-14.4%) | $10.01 M(-7.6%) | $34.92 M(+9.5%) |
| Sept 2018 | - | $10.84 M(+142.5%) | $31.89 M(-3.8%) |
| June 2018 | - | $4.47 M(-53.4%) | $33.14 M(-5.2%) |
| Mar 2018 | - | $9.59 M(+37.4%) | $34.94 M(-14.4%) |
| Dec 2017 | $40.81 M(+66.9%) | $6.98 M(-42.3%) | $40.81 M(+2.3%) |
| Sept 2017 | - | $12.10 M(+93.0%) | $39.90 M(+2.0%) |
| June 2017 | - | $6.27 M(-59.4%) | $39.12 M(+22.8%) |
| Mar 2017 | - | $15.46 M(+154.7%) | $31.86 M(+30.3%) |
| Dec 2016 | $24.45 M(-38.7%) | $6.07 M(-46.4%) | $24.45 M(-29.1%) |
| Sept 2016 | - | $11.32 M(-1252.3%) | $34.50 M(+7.5%) |
| June 2016 | - | -$982.00 K(-112.2%) | $32.09 M(-27.0%) |
| Mar 2016 | - | $8.04 M(-50.1%) | $43.97 M(+10.2%) |
| Dec 2015 | $39.91 M(-0.2%) | $16.12 M(+81.0%) | $39.91 M(+3.5%) |
| Sept 2015 | - | $8.91 M(-18.3%) | $38.55 M(+4.1%) |
| June 2015 | - | $10.90 M(+173.6%) | $37.03 M(+21.9%) |
| Mar 2015 | - | $3.98 M(-73.0%) | $30.37 M(-24.0%) |
| Dec 2014 | $39.98 M(+58.9%) | $14.76 M(+99.8%) | $39.98 M(+20.3%) |
| Sept 2014 | - | $7.39 M(+74.2%) | $33.23 M(-0.4%) |
| June 2014 | - | $4.24 M(-68.8%) | $33.37 M(+2.1%) |
| Mar 2014 | - | $13.60 M(+69.8%) | $32.69 M(+29.9%) |
| Dec 2013 | $25.16 M(+138.6%) | $8.01 M(+6.4%) | $25.17 M(+14.5%) |
| Sept 2013 | - | $7.53 M(+111.2%) | $21.97 M(+32.0%) |
| June 2013 | - | $3.56 M(-41.3%) | $16.65 M(-9.1%) |
| Mar 2013 | - | $6.07 M(+26.1%) | $18.31 M(+73.5%) |
| Dec 2012 | $10.55 M(+3.7%) | $4.81 M(+118.6%) | $10.55 M(-19.1%) |
| Sept 2012 | - | $2.20 M(-57.9%) | $13.04 M(-5.6%) |
| June 2012 | - | $5.22 M(-409.2%) | $13.82 M(+92.0%) |
| Mar 2012 | - | -$1.69 M(-123.1%) | $7.20 M(-29.2%) |
| Dec 2011 | $10.17 M(+29.5%) | $7.31 M(+145.5%) | $10.17 M(+53.3%) |
| Sept 2011 | - | $2.98 M(-313.1%) | $6.63 M(-4.7%) |
| June 2011 | - | -$1.40 M(-208.6%) | $6.96 M(-23.6%) |
| Mar 2011 | - | $1.29 M(-65.9%) | $9.12 M(+16.1%) |
| Dec 2010 | $7.85 M(+153.8%) | $3.77 M(+14.0%) | $7.85 M(+8.3%) |
| Sept 2010 | - | $3.31 M(+334.9%) | $7.25 M(+74.3%) |
| June 2010 | - | $759.90 K(+3796.9%) | $4.16 M(-1.3%) |
| Mar 2010 | - | $19.50 K(-99.4%) | $4.21 M(+36.1%) |
| Dec 2009 | $3.09 M(-9.2%) | $3.17 M(+1390.0%) | $3.09 M(+177.8%) |
| Sept 2009 | - | $212.60 K(-73.8%) | $1.11 M(-50.3%) |
| June 2009 | - | $812.70 K(-174.0%) | $2.24 M(-42.1%) |
| Mar 2009 | - | -$1.10 M(-192.5%) | $3.87 M(+13.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2008 | $3.41 M(-24.2%) | $1.19 M(-11.3%) | $3.41 M(+3501.7%) |
| Sept 2008 | - | $1.34 M(-45.2%) | $94.60 K(-97.1%) |
| June 2008 | - | $2.44 M(-256.5%) | $3.27 M(+19.9%) |
| Mar 2008 | - | -$1.56 M(-26.7%) | $2.72 M(-39.4%) |
| Dec 2007 | $4.49 M(+124.5%) | -$2.13 M(-147.1%) | $4.49 M(-27.6%) |
| Sept 2007 | - | $4.51 M(+137.7%) | $6.20 M(+149.5%) |
| June 2007 | - | $1.90 M(+807.3%) | $2.49 M(-7.4%) |
| Mar 2007 | - | $209.20 K(-150.6%) | $2.69 M(+34.2%) |
| Dec 2006 | $2.00 M(-69.0%) | -$413.70 K(-152.2%) | $2.00 M(+13.6%) |
| Sept 2006 | - | $793.00 K(-62.2%) | $1.76 M(-77.0%) |
| June 2006 | - | $2.10 M(-540.9%) | $7.66 M(+51.7%) |
| Mar 2006 | - | -$475.80 K(-27.2%) | $5.05 M(-21.8%) |
| Dec 2005 | $6.45 M(-72.9%) | -$653.90 K(-109.8%) | $6.45 M(-47.6%) |
| Sept 2005 | - | $6.69 M(-1402.7%) | $12.31 M(+101.5%) |
| June 2005 | - | -$513.60 K(-155.3%) | $6.11 M(+17.8%) |
| Mar 2005 | - | $928.80 K(-82.1%) | $5.19 M(-78.2%) |
| Dec 2004 | $23.82 M(+1084.1%) | $5.20 M(+959.4%) | $23.82 M(+12.2%) |
| Sept 2004 | - | $491.00 K(-134.2%) | $21.23 M(-3.8%) |
| June 2004 | - | -$1.44 M(-107.3%) | $22.07 M(+0.3%) |
| Mar 2004 | - | $19.57 M(+650.6%) | $22.00 M(+993.2%) |
| Dec 2003 | $2.01 M(+506.0%) | $2.61 M(+96.0%) | $2.01 M(+155.7%) |
| Sept 2003 | - | $1.33 M(-188.1%) | $787.00 K(-266.2%) |
| June 2003 | - | -$1.51 M(+262.7%) | -$473.60 K(-192.4%) |
| Mar 2003 | - | -$416.00 K(-130.1%) | $512.80 K(+54.5%) |
| Dec 2002 | $332.00 K(-107.7%) | $1.38 M(+1891.4%) | $331.90 K(-117.7%) |
| Sept 2002 | - | $69.40 K(-113.3%) | -$1.88 M(-45.3%) |
| June 2002 | - | -$522.60 K(-12.4%) | -$3.43 M(-3.2%) |
| Mar 2002 | - | -$596.90 K(-27.8%) | -$3.55 M(-17.8%) |
| Dec 2001 | -$4.31 M(+129.1%) | -$826.80 K(-44.4%) | -$4.31 M(+41.0%) |
| Sept 2001 | - | -$1.49 M(+134.6%) | -$3.06 M(+11.9%) |
| June 2001 | - | -$634.30 K(-53.5%) | -$2.74 M(-0.7%) |
| Mar 2001 | - | -$1.37 M(-419.9%) | -$2.75 M(+46.2%) |
| Dec 2000 | -$1.88 M(-331.7%) | $426.80 K(-136.7%) | -$1.88 M(-21.4%) |
| Sept 2000 | - | -$1.16 M(+78.2%) | -$2.40 M(+156.5%) |
| June 2000 | - | -$652.50 K(+31.8%) | -$934.80 K(-4.8%) |
| Mar 2000 | - | -$495.00 K(+467.0%) | -$982.30 K(-220.9%) |
| Dec 1999 | $812.70 K(-76.1%) | -$87.30 K(-129.1%) | $812.70 K(-45.8%) |
| Sept 1999 | - | $300.00 K(-142.9%) | $1.50 M(-37.5%) |
| June 1999 | - | -$700.00 K(-153.8%) | $2.40 M(-53.8%) |
| Mar 1999 | - | $1.30 M(+116.7%) | $5.20 M(+52.9%) |
| Dec 1998 | $3.40 M(+30.8%) | $600.00 K(-50.0%) | $3.40 M(-38.2%) |
| Sept 1998 | - | $1.20 M(-42.9%) | $5.50 M(+31.0%) |
| June 1998 | - | $2.10 M(-520.0%) | $4.20 M(+75.0%) |
| Mar 1998 | - | -$500.00 K(-118.5%) | $2.40 M(-7.7%) |
| Dec 1997 | $2.60 M(-360.0%) | $2.70 M(-2800.0%) | $2.60 M(-360.0%) |
| Sept 1997 | - | -$100.00 K(-133.3%) | -$1.00 M(-28.6%) |
| June 1997 | - | $300.00 K(-200.0%) | -$1.40 M(-22.2%) |
| Mar 1997 | - | -$300.00 K(-66.7%) | -$1.80 M(-14.3%) |
| Dec 1996 | -$1.00 M(-37.5%) | - | - |
| Nov 1996 | - | -$900.00 K(+80.0%) | -$2.10 M(+31.3%) |
| Aug 1996 | - | -$500.00 K(+400.0%) | -$1.60 M(+23.1%) |
| Aug 1996 | -$1.60 M(-5.9%) | - | - |
| May 1996 | - | -$100.00 K(-83.3%) | -$1.30 M(-23.5%) |
| Feb 1996 | - | -$600.00 K(+50.0%) | -$1.70 M(+13.3%) |
| Nov 1995 | - | -$400.00 K(+100.0%) | -$1.50 M(-11.8%) |
| Aug 1995 | -$1.70 M(-29.2%) | -$200.00 K(-60.0%) | -$1.70 M(-22.7%) |
| May 1995 | - | -$500.00 K(+25.0%) | -$2.20 M(+15.8%) |
| Feb 1995 | - | -$400.00 K(-33.3%) | -$1.90 M(-24.0%) |
| Nov 1994 | - | -$600.00 K(-14.3%) | -$2.50 M(+4.2%) |
| Aug 1994 | -$2.40 M(+380.0%) | -$700.00 K(+250.0%) | -$2.40 M(+41.2%) |
| May 1994 | - | -$200.00 K(-80.0%) | -$1.70 M(+13.3%) |
| Feb 1994 | - | -$1.00 M(+100.0%) | -$1.50 M(+200.0%) |
| Nov 1993 | - | -$500.00 K | -$500.00 K |
| Aug 1993 | -$500.00 K | - | - |
FAQ
- What is Anika Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Anika Therapeutics?
- What is Anika Therapeutics annual CFO year-on-year change?
- What is Anika Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Anika Therapeutics?
- What is Anika Therapeutics quarterly CFO year-on-year change?
- What is Anika Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Anika Therapeutics?
- What is Anika Therapeutics TTM CFO year-on-year change?
What is Anika Therapeutics annual cash flow from operations?
The current annual CFO of ANIK is -$1.79 M
What is the all time high annual CFO for Anika Therapeutics?
Anika Therapeutics all-time high annual cash flow from operations is $40.81 M
What is Anika Therapeutics annual CFO year-on-year change?
Over the past year, ANIK annual cash flow from operations has changed by -$6.20 M (-140.55%)
What is Anika Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ANIK is $5.02 M
What is the all time high quarterly CFO for Anika Therapeutics?
Anika Therapeutics all-time high quarterly cash flow from operations is $19.57 M
What is Anika Therapeutics quarterly CFO year-on-year change?
Over the past year, ANIK quarterly cash flow from operations has changed by -$1.47 M (-22.65%)
What is Anika Therapeutics TTM cash flow from operations?
The current TTM CFO of ANIK is $7.46 M
What is the all time high TTM CFO for Anika Therapeutics?
Anika Therapeutics all-time high TTM cash flow from operations is $43.97 M
What is Anika Therapeutics TTM CFO year-on-year change?
Over the past year, ANIK TTM cash flow from operations has changed by +$12.40 M (+250.84%)